

GenCore version 5.1.4_p5_4579
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: April 23, 2003, 12:53:20 ; Search time 40 Seconds
(without alignments)
1938.797 Million cell updates/sec

Title: US-09-635-949-34

Perfect score: 3289

Sequence: 1 MDPLLALVSSLYLQAAAE.....TGEIGLDVSLKKGHCSEER 582

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A_Geneseq.101002.*

1:	/SID52/gcgdata/geneseq/geneseqp-emb1/AA1980.DAT.*
2:	/SID52/gcgdata/geneseq/geneseqp-emb1/AA1981.DAT.*
3:	/SID52/gcgdata/geneseq/geneseqp-emb1/AA1982.DAT.*
4:	/SID52/gcgdata/geneseq/geneseqp-emb1/AA1983.DAT.*
5:	/SID52/gcgdata/geneseq/geneseqp-emb1/AA1984.DAT.*
6:	/SID52/gcgdata/geneseq/geneseqp-emb1/AA1985.DAT.*
7:	/SID52/gcgdata/geneseq/geneseqp-emb1/AA1986.DAT.*
8:	/SID52/gcgdata/geneseq/geneseqp-emb1/AA1987.DAT.*
9:	/SID52/gcgdata/geneseq/geneseqp-emb1/AA1988.DAT.*
10:	/SID52/gcgdata/geneseq/geneseqp-emb1/AA1989.DAT.*
11:	/SID52/gcgdata/geneseq/geneseqp-emb1/AA1990.DAT.*
12:	/SID52/gcgdata/geneseq/geneseqp-emb1/AA1991.DAT.*
13:	/SID52/gcgdata/geneseq/geneseqp-emb1/AA1992.DAT.*
14:	/SID52/gcgdata/geneseq/geneseqp-emb1/AA1993.DAT.*
15:	/SID52/gcgdata/geneseq/geneseqp-emb1/AA1994.DAT.*
16:	/SID52/gcgdata/geneseq/geneseqp-emb1/AA1995.DAT.*
17:	/SID52/gcgdata/geneseq/geneseqp-emb1/AA1996.DAT.*
18:	/SID52/gcgdata/geneseq/geneseqp-emb1/AA1997.DAT.*
19:	/SID52/gcgdata/geneseq/geneseqp-emb1/AA1998.DAT.*
20:	/SID52/gcgdata/geneseq/geneseqp-emb1/AA1999.DAT.*
21:	/SID52/gcgdata/geneseq/geneseqp-emb1/AA2000.DAT.*
22:	/SID52/gcgdata/geneseq/geneseqp-emb1/AA2001.DAT.*
23:	/SID52/gcgdata/geneseq/geneseqp-emb1/AA2002.DAT.*

Prod. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	3289	100.0	582	22	Human PRO17 protei
2	3097.5	94.2	546	22	Clone 16467945.0.8
3	2820	85.7	509	20	Amino acid sequenc
4	2820	85.7	509	22	Human PRO polypept
5	2820	85.7	509	22	Human PRO334 prote
6	1096	33.3	554	22	Human polypeptide
7	1096	33.3	554	22	Human EXMAD-2 SBO
8	1096	33.3	554	23	Human EGF motif-co
9	1092.5	33.2	553	23	Human EGF motif-co
10	1091.5	33.2	553	21	Human TANGO 212.

11	1091.5	33.2	553	22	Human polypeptide,
12	1091.5	33.2	553	23	Human EGF motif-co
13	1091.5	33.2	554	23	Human EGF motif-co
14	1091.5	33.2	559	23	Human EGF motif-co
15	1084	33.0	573	22	Human polypeptide
16	1076.5	32.7	553	20	protein encoded by
17	1068.5	32.5	551	23	kat protein isolat
18	1051.5	32.0	183	21	Human ORFX ORF1849
19	1041.5	31.7	502	23	Human EGF motif-co
20	1041.5	31.7	537	23	Human EGF motif-co
21	1039.5	31.6	537	20	Protein encoded by
22	1027.5	31.2	211	22	Human polypeptide
23	879.5	26.7	331	22	Human EGF motif-co
24	879.5	26.7	338	22	Human EGF motif-co
25	879.5	26.7	338	21	Human PRO320 prote
26	879.5	26.7	338	21	Amino acid sequenc
27	879.5	26.7	338	21	Human PRO320 antit
28	873.5	26.6	333	21	Murine TANGO 212.
29	845.5	25.7	284	21	Kat TGP-beta homol
30	845.5	25.7	284	22	Skin cell protein,
31	845.5	25.7	284	23	Rat protein isolat
32	644.5	19.6	251	22	Human cDNA seq ID
33	644.5	19.6	251	22	Human novel secret
34	594	18.1	164	23	Human EGF motif-co
35	592.5	18.0	123	22	Human PRO16 protei
36	516	15.7	94	21	Human ORFX ORF1846
37	409.5	12.5	100	20	EGF motif containi
38	409.5	12.5	100	23	Human EGF motif-co
39	407	12.4	2809	23	Human fibrillin 3
40	404	12.3	87	22	Clone 16467945.0.8
41	402	12.2	333	21	Amino acid sequenc
42	397.5	12.1	2912	22	Novel human diagno
43	393.5	12.0	1118	22	Human fibrillin-11
44	381.5	11.6	576	22	Human protein SEQ
45	381.5	11.6	576	22	Human protein SEQ

ALIGNMENTS

RESULT 1

AA870547
ID AA870547 standard; Protein; 582 AA.

XX
AC AA870547;

XX
DT 09-MAY-2001 (first entry)

XX
DE Human PRO17 protein sequence SFQ ID NO:34

XX
KW Human; PRO; PROX; cytosolic; immunomodulatory; reproduction;

XX
KW gene therapy; cell proliferation; differentiation disorder; cancer;

XX
KW immune associated disorder; gestational disease; pre-clampsia.

XX
OS Homo sapiens.

XX
PN WO200110902-A2.

XX
PD 15-FEB-2001.

XX
PF 11-AUG-2000; 2000WO-US21857.

XX
PR 11-AUG-1999; 99US-0148433.

XX
PR 10-AUG-2000; 2000US-0148433.

XX
PA (CURA-) CURAGEN CORP.

XX
PI Shinkets RA, Fernandes E;

XX
DR WPI; 2001-147509/15.

XX
DR N-PSDB; AAF74448.

XX
PT Nucleic acids encoding secreted polypeptides, designated PROX


```

Db 284 PPIINRPTSKPTTRTPKPTPIPTPPPPPLPTLPTLPTTTPERTTGLTTIAPAS 343
QY 380 TPFGGTVDNKRVQTDQKPRQGVFIPIRQPSNDLFIPIFERGVSAADDEAKDDPGVLVHSC 439
DB 344 TPFGGTVDNKRVQTDQKPRQGVFIPIRQPSNDLFIPIFERGVSAADDEAKDDPGVLVHSC 403
QY 440 NFDKGLCGWIREKNDLHWEPIRDPAGGYLTVSAAKAPGGKAARLVPLGRMLHSGDLG 499
DB 404 NFDHGI/CGWIREKNDLHWEPIRDPAGGYLTVSAAKAPGGKAARLVPLGRMLHSGDLG 463
QY 500 LSFHRKVTGLHSGTGLQVVRKHCARCAALWGRNGCHGWRTQTITLRGADIKSVVFKGPKR 559
DB 464 LSFHRKVTGLHSGTGLQVVRKHCARCAALWGRNGCHGWRTQTITLRGADIKSVVFKGPKR 523
QY 560 RGTGRI/IGLDDVSLAKKGCHSRK 582
DB 524 RGTGRI/IGLDDVSLAKKGCHSRK 546

RESULT 3
ID AAY13397 standard; Protein: 509 AA.
XX
AC AAY13397;
XX
DT 25-JUN-1999 (first entry)
XX
DE Amino acid sequence of protein PRO334.
XX
KW Secreted protein; transmembrane protein; human; enterocolitis;
KW Zollinger-Ellison syndrome; gastrointestinal ulceration;
KW congenital microvillus atrophy; skin disease; cell growth;
KW abnormal keratinocyte differentiation; psoriasis; epithelial cancer;
KW Parkinson's disease; Alzheimer's disease; ALS; neuropathy;
KW fibromodulin; dermal scarring; Usher Syndrome; Atrophia areata;
KW anti-thrombotic; wound healing; tissue repair.
XX
OS Homo sapiens.
XX
PN WO9914128-A2.
XX
PD 25-MAR-1999.
XX
PF 16-SEP-1998; 98WO-US19330..
XX
PR 25-NOV-1997; 97US-0066840.
PR 17-SEP-1997; 97US-0059113.
PR 17-SEP-1997; 97US-0059115.
PR 17-SEP-1997; 97US-0059117.
PR 17-SEP-1997; 97US-0059119.
PR 17-SEP-1997; 97US-0059121.
PR 17-SEP-1997; 97US-0059122.
PR 18-SEP-1997; 97US-0059184.
PR 18-SEP-1997; 97US-0059263.
PR 15-OCT-1997; 97US-0062125.
PR 17-OCT-1997; 97US-0062285.
PR 17-OCT-1997; 97US-0062287.
PR 21-OCT-1997; 97US-0063486.
PR 24-OCT-1997; 97US-0062814.
PR 24-OCT-1997; 97US-0062816.
PR 24-OCT-1997; 97US-0063045.
PR 24-OCT-1997; 97US-0063120.
PR 24-OCT-1997; 97US-0063121.
PR 24-OCT-1997; 97US-0063127.
PR 24-OCT-1997; 97US-0063128.
PR 27-OCT-1997; 97US-0063329.
PR 27-OCT-1997; 97US-0063327.
PR 28-OCT-1997; 97US-0063541.
PR 28-OCT-1997; 97US-0063542.
PR 28-OCT-1997; 97US-0063544.
PR 28-OCT-1997; 97US-0063549.
PR 28-OCT-1997; 97US-0063550.

```

```

PR 28-OCT-1997; 97US-0063564.
PR 29-OCT-1997; 97US-0063435.
PR 29-OCT-1997; 97US-0063704.
PR 29-OCT-1997; 97US-0063732.
PR 29-OCT-1997; 97US-0063738.
PR 29-OCT-1997; 97US-0063734.
PR 29-OCT-1997; 97US-0064215.
PR 29-OCT-1997; 97US-0063735.
PR 31-OCT-1997; 97US-0063870.
PR 31-OCT-1997; 97US-0064103.
PR 03-NOV-1997; 97US-0064248.
PR 07-NOV-1997; 97US-0064809.
PR 12-NOV-1997; 97US-0065186.
PR 17-NOV-1997; 97US-0065846.
PR 18-NOV-1997; 97US-0065693.
PR 21-NOV-1997; 97US-0066120.
PR 21-NOV-1997; 97US-0066364.
PR 24-NOV-1997; 97US-0066772.
PR 24-NOV-1997; 97US-0066466.
PR 24-NOV-1997; 97US-0066770.
PR 24-NOV-1997; 97US-0066511.
PR 24-NOV-1997; 97US-0066453.
XX
PA (GETH ) GENENTECH INC.
XX
CH Chen J., Goddard A., Gurney AL., Pennica D., Wood WI., Yuan J.;
XX
WPI; 1999-229533/19.
XX
N-PSDB; AAX52268..
XX
New isolated human genes and polypeptides used in, e.g. treatment of
XX
gastrointestinal ulceration
XX
Claim 12; Fig 110; 320pp; English.
XX
AAY13344-403 represent secreted and transmembrane human proteins.
XX
The cDNA sequences are obtained from cDNA libraries, prepared from
XX
fetal lung, fetal kidney, fetal brain, fetal liver and fetal retina.
XX
The encoded polypeptides have specific uses based on their homology to
XX
known polypeptides, e.g. PRO211 and PRO217 can be used for disorders
XX
associated with the preservation and maintenance of gastrointestinal
XX
mucosa and the repair of acute and chronic mucosal lesions
XX
(e.g. enterocolitis, Zollinger-Ellison syndrome, gastrointestinal
XX
ulceration and congenital microvillus atrophy), skin diseases associated
XX
with abnormal keratinocyte differentiation (e.g. psoriasis, epithelial
XX
cancers such as lung squamous cell carcinoma of the vulva and gliomas),
XX
potent effects on cell growth and development, discases related to
XX
growth or survival of nerve cells including Parkinson's disease,
XX
Alzheimer's disease, ALS, neuropathies or cancer. PRO265 can be used as
XX
for fibromodulin, e.g. for reducing dermal scarring. PRO264 can be used
XX
as a target for anti-tumor drugs. PRO533 may be used in the treatment
XX
of Usher Syndrome or Atrophia areata. PRO269 can be used as an
XX
anti-thrombotic agent. PRO287 polypeptides and portions may have
XX
therapeutic applications in wound healing and tissue repair. PRO317 can
XX
be used for treating problems of the kidney, uterus, endometrium, blood
XX
vessels, or related tissue, e.g. in the heart of genital tract.
XX
Sequence 509 AA;
XX
Query Match 85.7%; Score 2820; DB 20; Length 509;
Best Local Similarity 90.9%; Pred. No. 9.8e-164;
Matches 501; Conservative 0; Mismatches 4; Indels 46; Gaps 2;
QY 1 MDFLLALVLVSSLYLQAAAEFDGRWPRQIVSSIGLCRYGGRIDCCGWAROSWGQCPFY 60
DB 1 MDFLLALVLVSSLYLQAAAEFDGRWPRQIVSSIGLCRYGGRIDCCGWAROSWGQCP-- 58
QY 61 VLQRRIARICQLKAVQCPRCKHGECIGPNKCKCHPGYAGKTCIQVLNECGLKPRCKHR 120
DB 59 -----VCOPRCKHGECIGPNKCKCHPGYAGKTCINODINECGIKPRCKHR 103
QY 121 CMNTYGVSTCYCLNGYMLMPCGSSSALTCSMANCYQCDVVYKGOIRCOCPSPGLQAPD 180

```

Db 104 CMNTYGSYKCYCLNGYMIHPDSCSSALTCSSMANCOYGCDDVVKVGQIRCCQCPSPGILHLPD 163
 QY 181 GRTCDVDDECATGRASCPREFRCQVNTFGSYICKIKHGFDLMYIGKYQCHIDECISLGOY 240
 Db 164 GRTCDVDDECATGRASCPREFRCQVNTFGSYICKIKHGFDLMYIGKYQCHIDECISLGOY 223
 QY 241 QCSSEFARCYNVRSYKCKEKGQVQCHGICVYIPKVMIEPSGHVHPKONGTILKGDTCN 300
 Db 224 QCSSEFARCYNVRSYKCKEKGQVQCHGICVYIPKVMIEPSGHVHPKONGTILKGDTCN 283
 QY 301 NNWIPDVGSTWPPKTPYIPPIITNPTSKPTTRTPKPTPIPTPPPPPLPTELRLPLP 360
 Db 284 NNWIPDVGSTWPPKTPYIPPIITNPTSKPTTRTPKPTPIPTPPPPPLPTELRLPLP 343
 QY 361 PTPPERTGLTTIAPAASTPPGGITVDNRVQTDPOKPRGDFVIFPQPSNDLFEIFEIER 420
 Db 344 PTPPERTGLTTIAPAASTPPGGITVDNRVQTDPOKPRGDFVIFPQPSNDLFEIFEIER 386
 QY 421 GVSADDEAKDDPGVIVHSCNFDHGLCCWIREKINDIHWEPTRHPACQYLTIVSAAKAPGG 480
 Db 387 -----SVLVSCNFDHGLCCWIREKINDIHWEPTRHPACQYLTIVSAAKAPGG 434
 QY 481 KAARLVLPGLRMISDGLCLSRHKVTGLDSGTQLQVFPVKHGAUGAALNGRNGGHWROT 540
 Db 435 KAARLVLPGLRMISDGLCLSPRHKVTGLDSGTQLQVFPVKHGAUGAALNGRNGGHWROT 494
 QY 541 QITLGRADIKS 551
 Db 495 QITLGRADIKS 505
 RESULT 4
 AAU29049
 ID AAU29049 standard; Protein; 509 AA.
 XX AAU29049;
 AC AAU29049;
 DT 18-DEC-2001 (first entry)
 XX human PRO polypeptide sequence #26.
 DE
 XX PRO polypeptide; mammal; tumour; cancer; human; cattle; horse; sheep;
 KW dog; cat; pig; goat; rabbit; tumour necrosis factor alpha; TNF-alpha;
 KW blood; chondrocyte cell; cell proliferation; cell differentiation; colon;
 KW adrenal; lung; breast; prostate; rectum; cervix; liver; genetic disorder.
 XX Homo sapiens.
 OS
 XX
 PN W0200168848-A2.
 XX
 PD 20-SEP-2001.
 XX
 PF 28-FEB-2001; 2001WO-US06520.
 XX
 PR 01-MAR-2000; 2000WO-US05601.
 PR 02-MAR-2000; 2000WO-US05841.
 PR 03-MAR-2000; 2000US-187202P.
 PR 06-MAR-2000; 2000US-186968P.
 PR 14-MAR-2000; 2000US-189320P.
 PR 14-MAR-2000; 2000US-189328P.
 PR 15-MAR-2000; 2000WO-US06884.
 PR 21-MAR-2000; 2000US-190828P.
 PR 21-MAR-2000; 2000US-191007P.
 PR 21-MAR-2000; 2000US-191048P.
 PR 21-MAR-2000; 2000US-191314P.
 PR 28-MAR-2000; 2000US-192855P.
 PR 29-MAR-2000; 2000US-193032P.
 PR 29-MAR-2000; 2000US-193053P.
 PR 30-MAR-2000; 2000WO-US08439.
 PR 04-APR-2000; 2000US-194449P.
 PR 04-APR-2000; 2000US-194647P.
 PR 11-APR-2000; 2000US-195975P.
 PR 11-APR-2000; 2000US-196000P.

PR 11-APR-2000; 2000US-196187P.
 PR 11-APR-2000; 2000US-196690P.
 PR 11-APR-2000; 2000US-196820P.
 PR 18-APR-2000; 2000US-198121P.
 PR 18-APR-2000; 2000US-198585P.
 PR 25-APR-2000; 2000US-199397P.
 PR 25-APR-2000; 2000US-199550P.
 PR 25-APR-2000; 2000US-199654P.
 PR 03-MAY-2000; 2000US-201516P.
 PR 17-MAY-2000; 2000WO-US14705.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 30-MAY-2000; 2000WO-US14941.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 05-JUN-2000; 2000US-209832P.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 22-AUG-2000; 2000US-0644848.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 08-NOV-2000; 2000WO-US30952.
 PR 01-DEC-2000; 2000WO-US32678.
 PR 20-DEC-2000; 2000WO-US34956.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL,
 XX Pan J, Smith V, Watanabe CK, Wood WJ, Zhang Z;
 PI WPI: 2001-602746/68.
 DR N-PSDB: AAS45950.
 DR
 XX Novel nucleic acids encoding PRO polypeptides, used to diagnose the
 presence of tumours, such as prostate and breast tumours, in mammals and
 to screen for modulators of the compounds.
 XX Claim 11: Fig 52: 774pp; English.
 CC Sequences AAU29024-AAU29328 represent PRO polypeptides of the invention.
 CC The PRO polypeptides and their associated nucleic acids can be used to
 CC detect the presence of a tumour in a mammal by comparing the level of
 CC expression of a PRO polypeptide in a test sample of cells from the animal
 CC and a control sample of normal cells, whereby a higher level of
 CC expression in the test sample indicates the presence of a tumour in the
 CC mammal. Mammals include dogs, cats, cattle, horses, sheep, pigs, goats
 CC and rabbits but are preferably human. The polypeptides can be used to
 CC stimulate tumour necrosis factor (TNF) alpha release from human blood,
 CC when contacted with it. A specific polypeptide can be used to stimulate
 CC the proliferation or differentiation of chondrocyte cells. The PRO
 CC proteins can be used to determine the presence of tumours and also
 CC susceptibility to tumour development, particularly adrenal, lung, colon,
 CC breast, prostate, rectal, cervical, or liver tumours, in mammalian
 CC subjects. The oligonucleotide probes specific for the PRO nucleic acids
 CC can be used for genetic analysis of individuals with genetic disorders.
 XX
 SQ Sequence 509 AA:
 Query Match 85.7%; Score 2820; DB 22; Length 509;
 Best Local Similarity 90.9%; Pred. No. 9,8e-164;
 Matches 501; Conservative 0; Mismatches 4; Indels 46; Gaps 2;
 QY 1 MFDLLALVLVSSLYLQAAAEFDGRWPRQIVSSIGLCYGRGIDCGWAWKOSWQCPFY 60
 Db 1 MFDLLALVLVSSLYLQAAAEFDGRWPRQIVSSIGLCYGRGIDCGWAWKOSWQCP 58
 QY 61 VLQRRLARTRCQLKAVCGPCCKHGEICGNKCKCHPGYAGKTCIGVLFKGLKPPCKHR 120
 Db 59 -----VCQPRCKHGEICGNKCKCHPGYAGKTCIGVLFKGLKPPCKHR 104
 QY 121 CMNTYGSYKCYCLNGYMIHPDSCSSALTCSSMANCOYGCDDVVKVGQIRCCQCPSPGILHLPD 180
 Db 104 CMNTYGSYKCYCLNGYMIHPDSCSSALTCSSMANCOYGCDDVVKVGQIRCCQCPSPGILHLPD 164
 QY 181 GRTCDVDDECATGRASCPREFRCQVNTFGSYICKIKHGFDLMYIGKYQCHIDECISLGOY 240
 Db 164 GRTCDVDDECATGRASCPREFRCQVNTFGSYICKIKHGFDLMYIGKYQCHIDECISLGOY 224

QY 241 QCSSFARCYNVRGSKYKCKEGYGGDLTCVYIPKVMIEPSGDIHVPKNGTILKGDGN 300
DB 224 QCSSFARCYNVRGSKYKCKEGYGGDLTCVYIPKVMIEPSGDIHVPKNGTILKGDGN 283
QY 301 NNWIPDVGSTWMPKTPYIPPIITNRPTSKPTTRTPKPTPIPTPPPPPLTELRTPLP 360
DB 284 NNWIPDVGSTWMPKTPYIPPIITNRPTSKPTTRTPKPTPIPTPPPPPLTELRTPLP 343
QY 361 PTTPERPTTGLTTIAPAASTPPGCIITVDNRVQTDPOKPRGDFVIPRQPSNDLFEIFEIER 420
DB 344 PTTPERPTTGLTTIAPAASTPPGCIITVDNRVQTDPOKPRGDFV 386
QY 421 GVSADDEAKDDPGVLVHSCNFDHGLCGWIREKNDLHWEPIRDPAGGQYITVSAAKAPGG 480
DB 387 -----SVLVHSCNFDHGLCGWIREKNDLHWEPIRDPAGGQYITVSAAKAPGG 434
QY 481 KAARLVLPGLRMLHSGDLCLSFHKKVTGLHSGTLOVEVRKHGAAGALWGRNGHGWROT 540
DB 435 KAARLVLPGLRMLHSGDLCLSFHKKVTGLHSGTLOVEVRKHGAAGALWGRNGHGWROT 494
QY 541 QITLRGADIKS 551
DB 495 QITLRGADIKS 505

RESULT 5
AAH80265
ID AAB80265 standard; Protein; 509 AA.

AC AAB80265;
XX 24-APR-2001 (first entry)
XX Human PRO334 protein.

XX Human; PRO: dermatological; antipsoriatic; cytostatic; antiinflammatory;
KW antiaparkinsonian nootropic; neuroprotective; vulnerary; cardiac;
KW antiangiogenic; vasotropic; antiasthmatic; antirheumatic; cancer;
KW antiarthritic; antinfertility; antidiabetic; antiviral; diabetes;
KW ophthalmological; gene therapy; skin disease; gastrointestinal disorder;
KW ischaemia; inflammation.

XX Homo sapiens.

OS WO200104311-A1.

XX 18-JAN-2001.

XX 22-FEB-2000; 2000WO-0504414.

XX 07-JUL-1999; 99US-0143048.
XX 26-JUL-1999; 99US-0145698.
XX 28-JUL-1999; 99US-0146222.
XX 08-SEP-1999; 99WO-US20594.
XX 13-SEP-1999; 99WO-US20944.
XX 15-SEP-1999; 99WO-US21090.
XX 15-SEP-1999; 99WO-US21547.
XX 05-OCT-1999; 99WO-US23089.
XX 29-NOV-1999; 99WO-US28214.
XX 30-NOV-1999; 99WO-US28313.
XX 16-DEC-1999; 99WO-US30095.
XX 20-DEC-1999; 99WO-US30911.
XX 20-DEC-1999; 99WO-US30999.
XX 05-JAN-2000; 99WO-US00219.

XX (GETH) GENENTECH INC.

XX Ashkenazi AJ, Rotstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Flivaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ, Kljavin LJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;

XX

DR WPI: 2001-081051/09.
DR N-PSDB; AAF72426.

XX Sixty one nucleic acids encoding PRO polypeptides which are useful in
PT the treatment of skin diseases (e.g. psoriasis), cancers (e.g. lung
PT squamous cell carcinoma) and neurodegenerative diseases (e.g.
PT Alzheimer's disease)

XX Claim 1; Fig 110; 393pp; English.

XX The present sequence is one of sixty one novel secreted and
CC transmembrane PRO polypeptides. The PRO polypeptides are
CC useful for treating skin diseases (e.g. psoriasis), cancers (e.g. lung
CC squamous cell carcinoma), gastrointestinal disorders (e.g.
CC enterocolitis), neurodegenerative diseases (e.g. Alzheimer's disease,
CC parkinson's disease), wound repair, cardiovascular disorders (e.g.
CC endometrial bleeding angiogenesis, ischaemias such as coronary
CC ischaemia, atherosclerosis), inflammatory disorders (e.g. asthma,
CC rheumatoid arthritis, multiple sclerosis), infertility, AIDS and
CC diabetes and retinal disorders such as retinitis pigmentosum.
CC The PRO nucleic acids have applications in molecular biology, including
CC use as hybridization probes, and in chromosome and gene mapping.

XX Sequence 509 AA.

Query Match 85.7%; Score 2820; DB 22; Length 509;
Best Local Similarity 90.9%; Pred. No. 9.8e-164;
Matches 501; Conservative 0; Mismatches 4; Indels 46; Gaps 2;

QY 1 MDFLLALVLVSSLYLQAAAEFDGRWPRQIVSSIGLCRYGGRIDCCWGWARSQWGCQOPY 60
DB 1 MDFLLALVLVSSLYLQAAAEFDGRWPRQIVSSIGLCRYGGRIDCCWGWARSQWGCQOP-- 58
QY 61 VLHQRTAR:RCQLKAVCPCKHGCIGPNKCKCHPCYACKTCIOVLNCGCLKPRCKHR 120
DB 59 -----VCQPRCKHGCIGPNKCKCHPCYACKTCIOVLNCGCLKPRCKHR 103
QY 121 CMNTYSKYCYCLNGYMLMPDSCSSALTCSMANCOYGDVVKGOIRCOCPSPHGLAPD 180
DB 104 CMNTYSKYCYCLNGYMLMPDSCSSALTCSMANCOYGDVVKGOIRCOCPSPHGLAPD 163
QY 181 GRTCDVDDECATGRASCPFRQCVNTFGSYICKCHKGFELMYIGSKYQCHDIDECISGOY 240
DB 164 GRTCDVDDECATGRASCPFRQCVNTFGSYICKCHKGFELMYIGSKYQCHDIDECISGOY 223
QY 241 QCSSFARCYNVRGSKYKCKEGYGGDLTCVYIPKVMIEPSGDIHVPKNGTILKGDGN 300
DB 224 QCSSFARCYNVRGSKYKCKEGYGGDLTCVYIPKVMIEPSGDIHVPKNGTILKGDGN 283
QY 301 NNWIPDVGSTWMPKTPYIPPIITNRPTSKPTTRTPKPTPIPTPPPPPLTELRTPLP 360
DB 284 NNWIPDVGSTWMPKTPYIPPIITNRPTSKPTTRTPKPTPIPTPPPPPLTELRTPLP 343
QY 361 PTTPERPTTGLTTIAPAASTPPGCIITVDNRVQTDPOKPRGDFVIPRQPSNDLFEIFEIER 420
DB 344 PTTPERPTTGLTTIAPAASTPPGCIITVDNRVQTDPOKPRGDFV 386
QY 421 GVSADDEAKDDPGVLVHSCNFDHGLCGWIREKNDLHWEPIRDPAGGQYITVSAAKAPGG 480
DB 387 -----SVLVHSCNFDHGLCGWIREKNDLHWEPIRDPAGGQYITVSAAKAPGG 434
QY 481 KAARLVLPGLRMLHSGDLCLSFHKKVTGLHSGTLOVEVRKHGAAGALWGRNGHGWROT 540
DB 435 KAARLVLPGLRMLHSGDLCLSFHKKVTGLHSGTLOVEVRKHGAAGALWGRNGHGWROT 494
QY 541 QITLRGADIKS 551
DB 495 QITLRGADIKS 505

RESULT 6
AAM39156

PT preventing disorders associated with expression of EXMAD such as
 XX proliferative, immune and genetic disorders -
 PS Claim 1: Page 88-89; 129pp; English.
 XX The present invention provides the protein and coding sequences for 25
 CC novel extracellular matrix and adhesion-associated proteins (EXMADS).
 CC These are designated EXMAD-1, EXMAD-2, EXMAD-3, EXMAD-4, EXMAD-5,
 CC EXMAD-6, EXMAD-7, EXMAD-8, EXMAD-9, EXMAD-10, EXMAD-11, EXMAD-12,
 CC EXMAD-13, EXMAD-14, EXMAD-15, EXMAD-16, EXMAD-17, EXMAD-18, EXMAD-19,
 CC EXMAD-20, EXMAD-21, EXMAD-22, EXMAD-23, EXMAD-24 and EXMAD-25. They are
 CC useful in the prevention and treatment of cancers, cell proliferation,
 CC cardiovascular, reproductive, immune, musculoskeletal, developmental and
 CC gastrointestinal disorders and inflammation.
 XX
 SQ Sequence 554 AA;
 Query Match 33.3%; Score 1096; DB 22; Length 554;
 Best Local Similarity 37.9%; Pred. No. 6.7e-59;
 Matches 217; Conservative 99; Mismatches 168; Indels 88; Gaps 15;
 QY 34 GICRYGGRIDCCWGWARSQCCQPFYVLRORIRCOLKAVCPCKHGCICGNPKCK 93
 DB 39 GVCHYGTKLACCYGNRRNSKGVCE-----ATCEPGCKFCEYGNPKCR 81
 QY 94 CHPGYAGTKCIQVLENEGLKPRCKHRMNTYSGYKCYCLNGYMLMPDGSSSALTCMA 153
 DB 82 CFPYGTGTCSQDVNECGMKPRCPQHRCVNTHGSKYKPCLSGHMLMPDATCVNSNTCAMI 141
 QY 154 NCQYGCDDVVKGIKCCQSPGLQAPDGTCTVDDECATGRASCPRFCQVNTFGSYCK 213
 DB 142 NCQYSCDETEEGPQCLPSSGLRLAPNGRGLDIDECASGVICPYNRCVNTFGSYCK 201
 QY 214 CHKGFDLMYIGKYQCHDIDECSLQCYQSSFARCVNYRGSKYCKKQYQDGLTCVYI 273
 DB 202 CHIGFELQYISGRYDCIDINECTDMSHTCSHUANCFTQGSFKCKQYKGNGLRCSAI 261
 QY 274 PKVMTEPSGPIHVPKNGTILKGDGNNWIPDVGSTWPPKTPYIPILINRPTSKPTT 333
 DB 262 PENSVK-----EVLRAPGFI-----KORIKLLAHKNSMKKKA 294
 QY 334 R---PTPKPTPIPTPPPPPLTELRTPLPTTPTTGLTTIAPAASSTPPG----- 383
 DB 295 KIKNVTPEPTPTP-----KVNLPENYEE-----IVSRGNSHGCKGNEEK 338
 QY 384 ---GITYNMRVQ-----TDQPKNGDVPIPRQPSNDLFEIPIER-GVSADDEAKDDPG 433
 DB 339 MKEGLEDEKREKALKNDTEERSLRGDVFFPKVNEAGEFGLLVQKALTSLEHKADLN 398
 QY 434 VLVHSCNFDHGLCGWIREKNDLHWEPI-RDPAGQYLTVSAAKAPGGAARLVPLGLRL 492
 DB 399 ISV-DCSFNHIGCDKQDREDDFWNPADRONAIGFYMAVPALAGHKDKDIGRLKILLPDL 457
 QY 493 MHSGLCLCFRHKVGLHSHTQVFRKHGHAALWGRNGHG--WRQTOILT-RGAD- 548
 DB 458 QPQSFNCLLFYRLAGDKVGLRVPVK--NSNNALAWKTTSEDEKWKTKIQLYQGTDA 515
 QY 549 IKSVPKGRKRGHTGTEIGLDVSLKKQHCSE 580
 DB 516 TKSIIIEABERGKGTGEIADVGVLLVSLGLCPD 547
 RESULT 8
 AA015371
 ID AA015371 standard; protein; 554 AA.
 AC
 AA015371;
 XX
 DT 19-SEP-2002 (first entry)
 DE Human EGF motif-containing protein, SEQ ID No 32.
 XX Human;
 KW Human; epidermal growth factor molli; EGF molli; EGF6;

KW epithelial tissue growth; tissue repair; tissue regeneration;
 KW corneal transplant healing; skin graft; wound healing; cancer; leukaemia;
 KW nervous system disorder; infection; autoimmune disorder; inflammation;
 KW multiple sclerosis; anaemia; periodontal disease; haemophilia;
 KW fertility enhancement.
 XX Homo sapiens.
 OS WO200230977-A2.
 PN 18-APR-2002.
 PD 15-OCT-2001; 2001WO-US32257.
 PF 13-OCT-2000; 2000US-0687860.
 PR (HYSE-) HYSEQ INC.
 PA Asundi V, Ford JE, Drmanac RT, Liu C, Yamasaki V, Yeung G;
 PI Tang TY, Zhang J, Zhou P, Zhou H;
 XX WPI; 2002-426270/45.
 DR N-PSDB: AAL43906.
 XX Novel isolated epidermal growth factor molli polypeptide, termed EGF6,
 PT for treating cancer, nervous system disorders, immune deficiencies,
 PT autoimmune disorders, coagulation disorders and inflammatory conditions
 XX Claim 20: Page 181-183; 183pp; English.
 PS The invention comprises the amino acid and coding sequences of human
 CC epidermal growth factor (EGF) motif-containing proteins (EGF6 proteins).
 CC The DNA and protein sequences of the invention are useful for inhibiting
 CC the proliferation of cells expressing an EGF6 protein. The DNA and
 CC protein sequences of the invention are useful for stimulating epithelial
 CC tissue growth, for tissue repair and regeneration, corneal transplant
 CC healing, skin graft production and wound healing. The DNA and protein
 CC sequences are useful for treating cancer, leukaemia, nervous system
 CC disorders, infection, autoimmune disorders (e.g. multiple sclerosis),
 CC anaemia, periodontal diseases, haemophilia, inflammatory conditions, and
 CC for effecting bodily characteristics and fertility of male or female
 CC subjects. The present amino acid sequence represents a human EGF molli-
 CC containing protein.
 XX SQ Sequence 554 AA;
 Query Match 33.3%; Score 1096; DB 23; Length 554;
 Best Local Similarity 37.9%; Pred. No. 6.7e-59;
 Matches 217; Conservative 99; Mismatches 168; Indels 88; Gaps 15;
 QY 34 GICRYGGRIDCCWGWARSQCCQPFYVLRORIRCOLKAVCPCKHGCICGNPKCK 93
 DB 39 GVCHYGTKLACCYGNRRNSKGVCE-----ATCEPGCKFCEYGNPKCR 81
 QY 94 CHPGYAGTKCIQVLENEGLKPRCKHRMNTYSGYKCYCLNGYMLMPDGSSSALTCMA 153
 DB 82 CFPYGTGTCSQDVNECGMKPRCPQHRCVNTHGSKYKPCLSGHMLMPDATCVNSNTCAMI 141
 QY 154 NCQYGCDDVVKGIKCCQSPGLQAPDGTCTVDDECATGRASCPRFCQVNTFGSYCK 213
 DB 142 NCQYSCDETEEGPQCLPSSGLRLAPNGRGLDIDECASGVICPYNRCVNTFGSYCK 201
 QY 214 CHKGFDLMYIGKYQCHDIDECSLQCYQSSFARCVNYRGSKYCKKQYQDGLTCVYI 273
 DB 202 CHIGFELQYISGRYDCIDINECTDMSHTCSHUANCFTQGSFKCKQYKGNGLRCSAI 261
 QY 274 PKVMTEPSGPIHVPKNGTILKGDGNNWIPDVGSTWPPKTPYIPILINRPTSKPTT 333
 DB 262 PENSVK-----EVLRAPGFI-----KORIKLLAHKNSMKKKA 294
 QY 334 R---PTPKPTPIPTPPPPPLTELRTPLPTTPTTGLTTIAPAASSTPPG----- 383
 DB 295 KIKNVTPEPTPTP-----KVNLPENYEE-----IVSRGNSHGCKGNEEK 338
 QY 384 ---GITYNMRVQ-----TDQPKNGDVPIPRQPSNDLFEIPIER-GVSADDEAKDDPG 433
 DB 339 MKEGLEDEKREKALKNDTEERSLRGDVFFPKVNEAGEFGLLVQKALTSLEHKADLN 398
 QY 434 VLVHSCNFDHGLCGWIREKNDLHWEPI-RDPAGQYLTVSAAKAPGGAARLVPLGLRL 492
 DB 399 ISV-DCSFNHIGCDKQDREDDFWNPADRONAIGFYMAVPALAGHKDKDIGRLKILLPDL 457
 QY 493 MHSGLCLCFRHKVGLHSHTQVFRKHGHAALWGRNGHG--WRQTOILT-RGAD- 548
 DB 458 QPQSFNCLLFYRLAGDKVGLRVPVK--NSNNALAWKTTSEDEKWKTKIQLYQGTDA 515
 QY 549 IKSVPKGRKRGHTGTEIGLDVSLKKQHCSE 580
 DB 516 TKSIIIEABERGKGTGEIADVGVLLVSLGLCPD 547

Db 295 KIKNVTPEPTPTTP-----KVNLOPFNYEE-----IVSRGGNSHOCKKGNREK 338
 QY 384 ---GITVDNRVQ-----TDQPKRGDVFIPROPSNDLFEIFEIER-GVSADDEAKDDPG 433
 Db 339 MKESLEDEKREKALNDIEERSLRGDVFPKPVNEAGFGLILVORKALTSKLEHKADLN 398
 QY 434 VLVHSCNFDHGLCCWIRKKINDLHWEP1-RDPAGGQYLTVSAAKAGCGKAARLVLPGLRL 492
 Db 399 ISV-DKSFNIGICDWDKDEDDFDWPNADRNAIGFYMAVPALAGHKHKGIRLKLPLD 457
 QY 493 MHSQDCLSPRIHKVTGLHSGTGLQVFRKUGAHGAALWGRNGHG--WROTQITL-RGAD- 548
 Db 458 OPOSNFCILFDYRLAGDKVCKLRVFK--NSNNALAWERTTSEDEKWKTKLQLYQETDA 515
 QY 549 KSVVPKGEKRRGHTGKIGLDDVSLKKHCSE 580
 Db 516 TKSIIFEAERGKGTGEIAYDGVLLVSLGLCPD 547

RESULT 9
 AAO15361
 ID AAO15361 standard; Protein: 553 AA.
 AC AAO15361;
 XX
 XX 19-SEP-2002 (first entry)
 XX Human EGF motif-containing protein, SEQ ID NO 6.
 DE
 KW Human: epidermal growth factor motif; EGF motif; EGF16;
 KW epithelial tissue growth; tissue repair; tissue regeneration;
 KW corneal transplant healing; skin graft; wound healing; cancer; leukaemia;
 KW nervous system disorder; infection; autoimmune disorder; inflammation;
 KW multiple sclerosis; anaemia; periodontal disease; haemophilia;
 KW fertility enhancement.
 XX Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FT Misc-difference 357
 FT /note- "Encoded by WTA"
 XX
 XX W0200230977-A2.
 XX
 XX 18-APR-2002.
 XX
 XX 15-OCT-2001; 2001W0-0532257.
 XX
 XX 13-OCT-2000; 2000US-0687860.
 XX
 XX (HYSE-) HYSEQ INC.
 XX
 XX Asundi V, Ford JE, Drmanac RT, Liu C, Yamasaki V, Yeung G;
 XX Tang TY, Zhang J, Zhou P, Zhou H;
 XX
 XX WPI; 2002-426270/45.
 XX N-PSDB: AAL43890.
 XX
 XX Novel isolated epidermal growth factor motif polypeptide, termed EGF16,
 XX for treating cancer, nervous system disorders, immune deficiencies,
 XX autoimmune disorders, coagulation disorders and inflammatory conditions
 XX
 XX Example 3; Fig 5; 183pp; English.
 XX
 XX The invention comprises the amino acid and coding sequences of human
 XX epidermal growth factor (EGF) motif-containing proteins (EGF16 proteins).
 XX The DNA and protein sequences of the invention are useful for inhibiting
 XX the proliferation of cells expressing an EGF16 protein. The DNA and
 XX protein sequences of the invention are useful for stimulating epithelial
 XX tissue growth, for tissue repair and regeneration, corneal transplant
 XX healing, skin graft production and wound healing, the DNA and protein
 XX sequences are useful for treating cancer, leukaemia, nervous system

CC disorders, infection, autoimmune disorders (e.g. multiple sclerosis),
 CC anaemia, periodontal diseases, haemophilia, inflammatory conditions, and
 CC for effecting bodily characteristics and fertility of male or female
 CC subjects. The present amino acid sequence represents a human EGF motif
 CC containing protein.
 XX
 XX Sequence 553 AA;
 SO
 Query Match 33.2%; Score 1092.5; Db 23; Length 553;
 Best Local Similarity 47.7%; Pred. No. 136 58;
 Matches 215; Conservative 96; Mismatches 174; Indels 87; Gaps 14;
 QY 34 GLCRYGGRIDDCWGNAROSGQCPYVVLKRIARICGLKAVCPGPKCKHCEGCKNCK 93
 Db 39 GVCHGTGTLACCGWRRNSKGVCE-----ATCEGCKFGCEVFNCKR 81
 QY 94 CHEGVAGKTCIOVLNECGDKLPCKHCKMNTYGSYKCYCLNGYMLMDEGSSSALTQMA 154
 Db 82 CPEGYTGKTCGQVNRKCGMKPRCPCHRCVNTHGSKYKCFGLSGHMLMDIATVNSRFA 141
 QY 154 NCQYGGDVVKGQIRCOCPSPGLQAPDGRTCVDVDECATGRASCTPRPCQVNTFGSYCK 214
 Db 142 NCQYSCEDTEEGPQCLCPSSGLRLAPNGEDCLDIDECNSKXVLCFYNHRCVNTFGSYCK 201
 QY 214 CHKGFHJMYIGKYOCCHDIDECSLGOYOCSSPARYNVNKGSKYCKCKGYQGGELVYI 274
 Db 202 CHIGFELQYISGRYDGDINECTMDSHITCSHHANGFNTGSGSEKCKCKGYKONGLECAI 261
 QY 274 PKVMIEPSPGPIHVPKNGTILKGDITGNNWIPDVVSTWMPKTPYIPPIITNRPTSKPTT 333
 Db 262 PENSVK-----KVGRAPII-----KDRKKLILAHKNSMKKA 294
 QY 334 R---PTPKPTPTPTPPPPPLTELRTPLPTTPTPTPTGLTTIAPAASTPPG----- 383
 Db 295 KIKNVTPEPTPTTP-----KVNLOPFNYE-----IVSRGGNSHOCKKGNREK 338
 QY 384 ---GITVDNRVQ-----TDQPKRGDVFIPROPSNDLFEIFEIERGVSADDEAKDDPG 434
 Db 339 MKESLEDEKREKALNDIEERSLRGDVFPKPVNEAGFGLILVORKALTSKLEHKADLN 398
 QY 435 LVHSCNFDHGLCCWIRKKINDLHWEP1-RDPAGGQYLTVSAAKAGCGKAARLVLPGLRL 493
 Db 399 ISV-DKSFNIGICDWDKDEDDFDWPNADRNAIGFYMAVPALAGHKHKGIRLKLPLD 457
 QY 494 MHSQDCLSPRIHKVTGLHSGTGLQVFRKUGAHGAALWGRNGHG--WROTQITL-RGAD- 549
 Db 458 OPOSNFCILFDYRLAGDKVCKLRVFK--NSNNALAWERTTSEDEKWKTKLQLYQETDA 515
 QY 550 KSVVPKGEKRRGHTGKIGLDDVSLKKHCSE 580
 Db 516 TKSIIFEAERGKGTGEIAYDGVLLVSLGLCPD 546

RESULT 10
 AAO1423
 ID AAO1423 standard; Protein: 553 AA.
 XX
 XX AAO1423;
 XX
 XX 20-OCT-2000 (first entry)
 XX
 XX Human "TANGO 212".
 XX
 XX TANGO; 128; 140; 197; 212; 213; 224; 239; modulating agent; asthma;
 KW graft versus-host diseases; rheumatoid arthritis; psoriasis;
 KW inflammatory bowel disease; septic shock; ulcerative colitis;
 KW Crohn's disease; chronic myelogenous leukemia; cancer; liver
 KW disease; Hodgkin's disease; osteoarthritis; Lyme's disease;
 KW cachexia; autoimmune disease; myasthenia gravis; autoimmune diabetes;
 KW systemic lupus erythematosus; transgenic animal; diagnosis;
 KW prognosis; prophylactic; therapeutic; human.
 XX Homo sapiens.

XX WO200039284-A1.
 XX 06-JUL-2000.
 XX 23-DRC-1999: 99MO-US31025.
 XX 30-DRC-1998: 98US-0223546.
 XX (MILL-) MILLENNIUM PHARM INC.
 XX Holtzman DA;
 XX WPI: 2000-465743/40.
 XX N-PSDB; AAM47456.
 XX Novel nucleic acid sequences encoding TANGO-128, 140, 197, 212, 213,
 XX 224 and 239 polypeptides useful for the treatment of asthma, rheumatoid
 XX arthritis, psoriasis and autoimmune diseases
 XX Claim 8; Fig 5; 209pp; English.
 XX Nucleic acids encoding TANGO polypeptides are useful as modulating
 XX agents for regulating cellular processes like asthma, graft
 XX versus-host diseases, rheumatoid arthritis, psoriasis, inflammatory
 XX bowel disease, septic shock, ulcerative colitis, Crohn's disease,
 XX chronic myelogenous leukemia, cancer, liver disease, Hodgkin's
 XX disease, osteoarthritis, Lyme's disease, cachexia and autoimmune
 XX diseases e.g. myasthenia gravis, autoimmune diabetes and systemic
 XX lupus erythematosus. The nucleic acids are also useful for producing
 XX transgenic animals and the TANGO polypeptides themselves. Partial
 XX TANGO-128, 140, 197, 212, 213, 224, 239 sequences are useful in
 XX forensic biology, for diagnostic assays, prognostic assays,
 XX pharmacogenomics and for monitoring clinical trials. TANGO
 XX polypeptides are suitable for both prophylactic and therapeutic
 XX methods for treating a subject at risk of a disorder or having a
 XX disorder associated with aberrant TANGO expression. A wide range
 XX of cellular disorders can be treated.
 XX Sequence 553 AA:
 Query Match 33.2%; Score 1091.5; DB 21; Length 553;
 Best Local Similarity 37.7%; Pred. No. 1.2e-58;
 Matches 215; Conservative 96; Mismatches 173; Indels 87; Gaps 14;

QY 34 GLCRYGGRIDCCGWARQSGQCPFYVLRQRIARICOLKAVCPCKRGICGPNCK 93
 DB 39 GVCHYGTKLACCYGVRRNSKGVCE-----ATCEPGCKFGCEGVGNCK 81

QY 94 CHPGYAGKTCIQVINEGGLKPRCKHRCMTYGSYKCYCLNGYMLMDGSCSALTCSMA 153
 DB 82 CFPGYTGKTCSDVNEGCMKPRCPQHCRCVNTHGSKFCCLSGHMLPDCATVNSRTCAMI 141

QY 154 NCOYGDVVKQIIRCCPCSPGLQIAPDGRCTVDVDECATGRASCPFCVNTFGSYICK 213
 DB 142 NCOYSCDETEGQCCLPSSGLAFAPNGRCLDIDECASGKVICPNRRCVNTFGSYICK 201

QY 214 CHGFDMYTGKYCHDIDECSLGQYQSSSFARCVNRSYKCKEGYQGDGLTCVYI 273
 DB 202 CHICFETIQYISGRYDCIDINCKTMDSRTGSHANCFNTQGSFKCKQYKGNGLKCSAI 261

QY 274 PKVMIEPSCPIHVPKNGRILKQDTNNWIPVIGSTWPPKPTYPPIITNRPSTKPTT 333
 DB 262 PENSVK-----EVLRAFGTI-----KDRIKKLLAHKNSMKKA 294

QY 334 R---PTPKPTPTPTPPPPPLPTELRTPPTTPENPTTGLTTIAPAASTPPG----- 383
 DB 295 KIKNVTPEPTRTPTP-----KVNIOPENYEE-----IVSRGNSHGKCKNEK 338

QY 384 ---GITVDNRVQ-----TDPQKRGDVFPTROPFSNDLFEIFEIERGVSADDEAKDDPGV 434
 DB 339 MKRLEDEKREKALKNDIEERSLRGDFVFPKVNAGEFGLIIVQRKAITSKLEHRDLNI 398

QY 435 LVHSCNFDHGLCGWIREKNDLHWEPF--KDPAGGOYLTVSAAKAPCGKAARLVLPIGRIM 493
 DB 399 SV-DCSENFHICDWDKDRDDEWNPADRCNNAIGFYMAVPALAGHKDIGRUKLLPDLQ 457
 QY 494 HSGDCLSLFRHKVTGLHSGTGLQVFRKKGHAAGAAALWGRNGHG--WRQTQITL-RGAD-I 549
 DB 458 POSNFCILLFDYRLAGDKVKCLRVFK--NSNNALAEKTTSEDEKWKCKIQLYGTTAT 515
 QY 550 KSVFPGKGRRGHTGEIGLDDVSLRKKHCSE 580
 DB 516 KSIIFEAEERGKGTGEIADVGLVLSGLCPD 546

RESULT 11
 AAM93622
 ID AAM93622 standard; Protein: 553 AA.
 XX AC AAM93622;
 XX DT 06-NOV-2001 (first entry)
 XX Human polypeptide, SEQ ID NO: 3456.
 XX Human; full length cDNA; cDNA synthesis; oligo-capping.
 XX Homo sapiens.
 XX EP1130094-A2.
 XX 05-SEP-2001.
 XX 07-JUL-2000; 2000EP-0114089.
 XX 08-JUL-1999; 98JP-0194486.
 XX 11-JAN-2000; 2000JP-0118774.
 XX 02-MAY-2000; 2000JP-0183765.
 XX (HELI-) HELIX RES INST.
 XX Ota T, Nishikawa T, Isoqai T, Hayashi K, Ishii S, Kawai Y;
 XX Wakamatsu A, Sugiyama T, Nagai K, Kojima S, Otsuki T, Koqa H;
 XX WPI: 2001-524255/58.
 XX N-PSDB; AAK94555.
 XX 830 Primers useful for synthesizing full length cDNA clones and their
 XX use in genetic manipulation -
 XX Claim 8; SEQ ID NO 3456; 1380pp + sequence listing; English.
 XX The invention relates to primers for synthesizing full length cDNA
 XX clones. 830 cDNA molecules encoding a human protein have been
 XX isolated and nucleotide sequences of 5'- and 3'-ends of the cDNA
 XX molecules have been determined. Primers for synthesizing the full length
 XX cDNA are useful for clarifying the function of the protein encoded by
 XX the cDNA. The full length clones were obtained by construction of full
 XX length enriched cDNA libraries that were synthesised by the oligo-capping
 XX method. The primers enable the production of the full length cDNA easily
 XX without any special methods. The present sequence is a polypeptide
 XX encoded by a full length human cDNA of the invention.
 XX Note: The sequence data for this patent did not form part of the printed
 XX specification, but was obtained in CD-ROM format directly from EPO.
 XX Sequence 553 AA:

Query Match 33.2%; Score 1091.5; DB 22; Length 553;
 Best Local Similarity 37.7%; Pred. No. 1.2e-58;
 Matches 215; Conservative 96; Mismatches 173; Indels 87; Gaps 14;

QY 34 GLCRYGGRIDCCGWARQSGQCPFYVLRQRIARICOLKAVCPCKRGICGPNCK 93
 DB 39 GVCHYGTKLACCYGVRRNSKGVCE-----ATCEPGCKFGCEGVGNCK 81

QY 94 CHPGYAGKTCIOVLNEGLKPRCKKURKMNNTYGSYKCYCLNGYMLMPDSCSSALTCGSA 153
 DB 82 CFFCYCTKTCSDQVNECGKPKPCRCVNTGHSYKCPCLISCHMLMPDTCVNSRTICAM 141
 QY 154 NCOYGVGVKQIUKCQPSGKQLAPDKVTCVIVDKATCRASCPRFCVNTFGSYICK 213
 DB 142 NCOYSCDETEEGPQCLCPSSGLAPNGRDLIDECASGKVLCPYNNRCVNTFGSYICK 201
 QY 214 CHGCFDLMYIGKYQCHDIDECISGOYOCSSPARCYNVNGSYKCKGVOGGLTCVYI 273
 DB 202 CHGCFEIQYISGRYDCIDINECTMSHTCSHHANCFTQCSFKCKQYKONGLRCSAI 261
 QY 274 PKVMIEPSPGIHVPKNGTILKGDGTNNWNIPDVGSTWPPKTPYIPPIITNKPTSKPT 333
 DB 262 PENSVK-----EVLNAPGTI-----KDKIKKLLAHKNSMKKA 294
 QY 334 R---PTPKTPTPTPTPTPTPTPTPTPTPTPTPTPTPTPTPTPTPTPTPTPTPTPT 383
 DB 295 KIKNVTPEPTPTPT-----KVNLOPFNYYE-----IVSRGNSHGKCKGNEEK 338
 QY 384 ---GITVDNKVQ-----TDPQKPRGVDFIPQPSNDLPEIPEIRGVSAADDEAKDDPGV 434
 DB 339 MKKGLDEKREKKALEKNDIEERSLRGVDFIPKVNAGHGLITVORKALETSKLEKDLNI 398
 QY 435 LVHSCNFDHGLGCIWIREKNDLHWEPI-RDPAGGQYLTYSAAKAPGGAARLVPLGLRM 493
 DB 399 SV-DCSPNHCICDKQDREDDFNADRNALGPTMAVPALAGHKDDIGRLKLLPLDQ 457
 QY 494 HSGDGLSPRHKVTGLHSGTLOVYFKKHAAGALWGRNGCHG--WRQTOITLH-ROAD 549
 DB 458 PQSNFCLLDYRLAGDKVGLRVEVK--NSNNALAWKETTSEDEKWKTKGIQLYQGTDAT 515
 QY 550 KSVVFKGKKRKHGTGPIGLDDVSLKKGHCSE 580
 DB 516 KSIIFPAKCKKCKTORIAVDGVILVSGICPD 546

RESULT 12
 AAO15368
 ID AAO15368 standard; Protein: 553 AA.
 XX
 AC AAO15368:
 XX
 DT 19-SEP-2002 (first entry)
 XX
 DE Human EGF motif-containing protein, SPO ID No 24.
 XX
 KW Human; epidermal growth factor motif; EGF motif; EGFL6;
 KW epithelial tissue growth; tissue repair; tissue regeneration;
 KW corneal transplant healing; skin graft; wound healing; cancer; leukaemia;
 KW nervous system disorder; infection; autoimmune disorder; inflammation;
 KW multiple sclerosis; anaemia; periodontal disease; haemophilia;
 KW fertility enhancement.
 XX
 OS Homo sapiens.
 XX
 PN WC200230977-A2.
 XX
 PD 18-APR-2002.
 XX
 PE 15-OCT-2001; 2001WO-US32257.
 XX
 PR 13-OCT-2000; 2000US-0687860.
 XX
 PA (HYSK-) HYSKO INC.
 XX
 PI Asundi V, Ford JE, Ermanac RT, Liu C, Yamasaki V, Yeung G;
 PI Tang TY, Zhang J, Zhou P, Zhou H;
 XX
 DR WPI: 2002-426270/45.
 DR N-PSDB: AAL43901.
 XX
 PT Novel isolated epidermal growth factor motif polypeptide, termed EGFL6,

PT for treating cancer, nervous system disorders, immune deficiencies,
 PT autoimmune disorders, coagulation disorders and inflammatory conditions
 XX
 PS Claim 28; Page 167-169; 183pp; English.
 XX
 CC The invention comprises the amino acid and coding sequences of human
 CC epidermal growth factor (EGF) motif-containing proteins (EGFL6 proteins).
 CC The DNA and protein sequences of the invention are useful for inhibiting
 CC the proliferation of cells expressing an EGFL6 protein. The DNA and
 CC protein sequences of the invention are useful for stimulating epithelial
 CC tissue growth, for tissue repair and regeneration, corneal transplant
 CC healing, skin graft production and wound healing. The DNA and protein
 CC sequences are useful for treating cancer, leukaemia, nervous system
 CC disorders, autoimmune disorders (e.g. multiple sclerosis),
 CC anaemia, periodontal diseases, haemophilia, inflammatory conditions, and
 CC for effecting bodily characteristics and fertility of male or female
 CC subjects. The present amino acid sequence represents a human EGF motif-
 CC containing protein.
 XX
 SO Sequence 553 AA;
 Query Match 33.2%; Score 1091.5; DB 23; Length 553;
 Best Local Similarity 37.7%; Pred. No. 1,2e-58;
 Matches 215; Conservative 96; Mismatches 174; Indels 87; Gaps 14;
 QY 34 GICRYGGRIDCCWGAHRSWGCQHPYVLRQFIARICOLKAVCPQPKKRGFTGNPKCK 94
 DB 39 GVCYGTGKLCACGYGHRNSKGVCE-----ATCGKCKPFCRCVGNPKCR 81
 QY 94 CHPGYAGKTCIOVLNEGLKPRCKKURKMNNTYGSYKCYCLNGYMLMPDSCSSALTCGSA 153
 DB 82 CFFCYCTKTCSDQVNECGKPKPCRCVNTGHSYKCPCLISCHMLMPDTCVNSRTICAM 141
 QY 154 NCOYGVGVKQIUKCQPSGKQLAPDKVTCVIVDKATCRASCPRFCVNTFGSYICK 213
 DB 142 NCOYSCDETEEGPQCLCPSSGLAPNGRDLIDECASGKVLCPYNNRCVNTFGSYICK 201
 QY 214 CHGCFDLMYIGKYQCHDIDECISGOYOCSSPARCYNVNGSYKCKGVOGGLTCVYI 273
 DB 202 CHGCFEIQYISGRYDCIDINECTMSHTCSHHANCFTQCSFKCKQYKONGLRCSAI 261
 QY 274 PKVMIEPSPGIHVPKNGTILKGDGTNNWNIPDVGSTWPPKTPYIPPIITNKPTSKPT 333
 DB 262 PENSVK-----EVLNAPGTI-----KDKIKKLLAHKNSMKKA 294
 QY 334 R---PTPKTPTPTPTPTPTPTPTPTPTPTPTPTPTPTPTPTPTPTPTPTPTPTPT 383
 DB 295 KIKNVTPEPTPTPT-----KVNLOPFNYYE-----IVSRGNSHGKCKGNEEK 338
 QY 384 ---GITVDNKVQ-----TDPQKPRGVDFIPQPSNDLPEIPEIRGVSAADDEAKDDPGV 434
 DB 339 MKKGLDEKREKKALEKNDIEERSLRGVDFIPKVNAGHGLITVORKALETSKLEKDLNI 398
 QY 435 LVHSCNFDHGLGCIWIREKNDLHWEPI-RDPAGGQYLTYSAAKAPGGAARLVPLGLRM 493
 DB 399 SV-DCSPNHCICDKQDREDDFNADRNALGPTMAVPALAGHKDDIGRLKLLPLDQ 457
 QY 494 HSGDGLSPRHKVTGLHSGTLOVYFKKHAAGALWGRNGCHG--WRQTOITLH-ROAD 549
 DB 458 PQSNFCLLDYRLAGDKVGLRVEVK--NSNNALAWKETTSEDEKWKTKGIQLYQGTAT 515
 QY 550 KSVVFKGKKRKHGTGPIGLDDVSLKKGHCSE 580
 DB 516 KSIIFPAKCKKCKTORIAVDGVILVSGICPD 546
 RESULT 13
 AAO15370
 ID AAO15370 standard; Protein: 554 AA.
 XX
 AC AAO15370:
 XX

CC sequences are useful for treating cancer, leukaemia, nervous system disorders, infection, autoimmune disorders (e.g. multiple sclerosis), and anaemia, periodontal diseases, haemophilia, inflammatory conditions, and for effecting bodily characteristics and fertility of male or female subjects. The present amino acid sequence represents a human EGF motif-containing protein.

XX
SQ Sequence 559 AA;

Query Match 33.2%; Score 1091.5; DB 23; Length 559;
Best Local Similarity 37.7%; Pred. No. 1,30-58;
Matches 215; Conservative 96; Mismatches 173; Indels 87; Gaps 14;

QY 34 GLCRYGGRIDCCGWARQSGQCPYVLRQRIARICQIKAVCPCKHIGEGIPNCKK 93
DB 45 GVCHYGTGKLACCYGWRHNSKGVCE-----ATCEGCKRFGCVGNPKCR 87
QY 94 CHPGYAGKTCIOVLNKGCKLPRCKHRCNMNTYGYKCYCLNGYMLMPDGSSSALTCMA 153
DB 88 CFPGYGTGTCQDVNCGMKPRCPQIRCVNTHSGYKCFCLGHLMPDQATCVNSRTCAMI 147
QY 154 NCQYGCIVVKGQIRCCQCPSPGLQAPDRTCDVDPCATGRASCPRFCVNTFGSYICK 213
DB 148 NCQYSGEDTEEGPQCLCPSSGLAPLNGRDLIDECASGKVICPNRRCVNTHSGSYCK 207
QY 214 CHKGFDLMYIGGVYQCHIDIECSLGOYQCSFARCVNVRSGYKCKGEGVGDGLTCVYL 273
DB 208 CHIGFELOYISGNYDCIDINECTMSHTCSHANCNPTQCFKCKQGYKGMGLKCSAI 267
QY 274 PKVMIEPSPHVPKNGTILKIDGTNNNNWIPDVGTWPPPTPTPIITNPTSKPTT 333
DB 268 PENSVK-----EVLAPGTT-----KDRICKLLAHKNSMKKA 300
QY 334 K---PTPKPPTDTPPPPPPLPTELTPPTPTPTPTTGLTTTAPAASTPPG----- 383
DB 301 KIKNVPEPTPTTP-----KVNLOPFNVE-----IVSRGNSHGKCKNEEK 344
QY 384 ---GIIVDNVQ-----TDQPKRGDVTIPROPSNDLFEIFIEGVSADDEAKDDGV 434
DB 345 MKGLGDEKREKALANDIPERSLRGVPPKVNAGRFGLIVORKATLSKLEHKDINI 404
QY 435 LVHSCNFDIGLGGWIREKNDLWEPT-RDPAGQYLTYSAAKAPGGKAARVLPLGRLM 493
DB 405 SV-DGSEFNIGICDWKODREDDFNADRDNAIGFYMAVPALAGHKDGLKLLPLDLQ 463
QY 494 HSGDGLCSFHHKVTGLHSCVHLOVEVRKHGCAAGALWCRNGCHG--WROVQITL-RGAD-I 549
DB 464 PQSNFCLLFDYRLAGKVGKLRVFK--NSNNALWEKTTSEDEKWKTKIQLYQGTDAT 521
QY 550 KSVFKEGKRRGHTGEIGLDDVSLKKGKICSE 580
DB 522 KSIIFPAERKGGKTGRIVAGVILVSGICPD 552

RESULT 15

AA040942

ID AA040942 standard; Protein: 573 AA;

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

XX AC

PN W0200153312-A1.
XX 26-JUL-2001.
XX 26-DEC-2000; 2000WO-US34263.
XX 21-JAN-2000; 2000US-0488725.
XX 25-APR-2000; 2000US-052317.
XX 09-JUL-2000; 2000US-0598042.
XX 19-JUL-2000; 2000US-0620312.
XX 03-AUG-2000; 2000US-0653450.
XX 14-SEP-2000; 2000US-0662191.
XX 19-OCT-2000; 2000US-0693036.
XX 29-NOV-2000; 2000US-0727344.
XX (HYSE-) HYSEQ INC.
XX Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XR, Ren F, Wang D;
XX Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
XX Zhao QA, Zhou P, Goodrich R, Dimaane RT;
XX WPI; 2001-442253/47.
XX N-PSDB; AA160098.
XX Novel nucleic acids and polypeptides, useful for treating disorders
XX such as central nervous system injuries -
XX Example 2; SEQ ID NO 5873; 10078pp; English.
XX The invention relates to human nucleic acids (AA157798 AA163469) and
XX the encoded polypeptides (AA38642-AA42213) with neurotrophic,
XX immunosuppressant and cytostatic activity. The polynucleotides are useful
XX in gene therapy. A composition containing a polypeptide or polynucleotide
XX of the invention may be used to treat diseases of the peripheral nervous
XX system, such as peripheral nervous injuries, peripheral neuropathy and
XX localized neuropathies and central nervous system diseases, such as
XX Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
XX lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
XX utilisation of the activities such as: immune system suppression,
XX activation/inhibition activity, chemotactic/chemokinetic activity, haemostatic
XX and thrombolytic activity, cancer diagnosis and therapy, drug screening,
XX assays for receptor activity, arthritis and inflammation, leukaemia and
XX C.N.S disorders.
XX Note: The sequence data for this patent did not form part of the printed
XX specification.

SQ Sequence 573 AA;

Query Match 33.0%; Score 1084; DB 22; Length 574;
Best Local Similarity 37.8%; Pred. No. 3,7e-58;
Matches 219; Conservative 99; Mismatches 161; Indels 100; Gaps 18;

QY 34 GLCRYGGRIDCCGWARQSGQCPYVLRQRIARICQIKAVCPCKHIGEGIPNCKK 93
DB 56 GVCHYGTGKLACCYGWRHNSKGVCE-----ATCEGCKRFGCVGNPKCR 98
QY 94 CHPGYAGKTCIOVLNKGCKLPRCKHRCNMNTYGYKCYCLNGYMLMPDGSSSALTCMA 153
DB 99 CFPGYGTGTCQDVNCGMKPRCPQIRCVNTHSGYKCFCLGHLMPDQATCVNSRTCAMI 158
QY 154 NCQYGCIVVKGQIRCCQCPSPGLQAPDRTCDVDPCATGRASCPRFCVNTFGSYICK 213
DB 159 NCQYSGEDTEEGPQCLCPSSGLAPLNGRDLIDECASGKVICPNRRCVNTHSGSYCK 218
QY 214 CHKGFDLMYIGGVYQCHIDIECSLGOYQCSFARCVNVRSGYKCKGEGVGDGLTCVYL 273
DB 219 CHIGFELOYISGNYDCIDINECTMSHTCSHANCNPTQCFKCKQGYKGMGLKCSAI 278
QY 274 PKVMIEPSPHVPKNGTILKIDGTNNNNWIPDVGTWPPPTPTPIITNPTSKPTT 333
DB 279 PENSVK-----EVLAPGTT-----KDRICKLLAHKNSMKKA 311
QY 334 R---PTPKPPTDTPPPPPPLPTELTPPTPTPTTGLTTTAPAASTPPG----- 483

```
Db 312 KIKNVTPPTPTTP-----KVNIQPNYER-----[VSRGCGNSHCCKKCNERR 355
Qy 384 ----GITVDNRVOT-----DPOKP-RGDVFIPIQPSNDLFEIFEIER-GVSADDEAKDDP 432
Db 356 MKEGLPDEFKREKALKDXHRRERPFPGDVFFPKVNFAGEFGI.II.VORKAL/TSKLEKKADI 415
Qy 433 GVLVHSCNFDHGLCGWIREKNDLHWEPI-RDPAGGOYI.IVSAAKAPG-----GKAARL 485
Db 416 NISV-DCSFNHGICDWKQDREDDFDNFPADRONAIGFYNAV-----PGLWQGHKKDIGRL 469
Qy 486 VLPGLCHLHSHGDIQSFRHKVTGLHSGTIOVEVVRKHGAHGAALWGRNGCHG--WRQTQIT 543
Db 470 KIJLLPDLQPSNFCILIFDYRLAGDKVGLRVFVK--NSNNALAWKTTSEDEKWKTKIQ 527
Qy 544 L-RGAD-IKSVVFKGKRRGHTGETGLDDVSLKKGHCSE 580
Db 528 LYQGTATKSIIFEARCGKKTGETAVDGVLI.VSGICPD 566
```

Search completed: April 23, 2003, 13:01:06
Job time : 43 secs

